# CliniqueRx — Patient Guide ## Document control | Field | Value | | --- | --- | | Document version | Controlled Global-mode document 1.0 | | Date | August 30, 2026 | | Source-guide revision | September 20, 2026 — local workflows; verify availability in the deployed release | | PDFs | Local export of September 20, 2026; no new clinical or legal approval | | Targeted security revision | October 27, 2026 - initial MFA, browser remembrance and session duration; PDF export not updated | | Audience | Registered patients and people invited by a pharmacy | | Software target | Global production mode; verify the deployed release identity before use | | Screenshots | Use fictional people only | | Real-world use | **Governed by the active Global release and pharmacy-workspace controls** | > This guide explains how to use CliniqueRx. It does not provide medical advice or guarantee that treatment will be offered. A pharmacist must review the information and make the final decision. ## 1. What is CliniqueRx for? CliniqueRx lets you send information to your pharmacy before or during a consultation. Depending on the services your pharmacy has enabled, you can: - complete a form for a minor health concern; - prepare for a travel-health consultation; - keep parts of your profile up to date; - send a secure general message directly to your pharmacy or when none of the suggested assessments matches your concern; - view appointments and follow-ups; - reschedule or cancel an appointment when notice rules and available slots allow it. The form helps the pharmacist avoid missing an important question. It does not make a diagnosis or replace a conversation or examination. ## 2. In an emergency Do not wait for a response in CliniqueRx if you think you are experiencing an emergency. Call emergency services or go to the appropriate service. While completing a form, a message may tell you to obtain care promptly. Follow that instruction and do not continue only to finish the form. Submissions are not monitored at all times and do not guarantee an immediate response. ## 3. Create a patient account You must be at least **14 years old** to create a patient account. Account creation is blocked below that age. 1. Open the patient registration page and enter an email address that only you can access. 2. Request the protected link. If it does not arrive, check your junk-mail folder and request a new link when needed. 3. Open that personal link before it expires. 4. Enter your name, required date of birth in **DD-MM-YYYY** format, optional phone number, and a unique password, then confirm the password. 5. Read and accept the interim user agreement; the Privacy Notice remains a separate document. 6. Create the account. Sign-in continues automatically through the usual checks; complete any additional step shown. You reach **Home** or the workflow you were returning to. Add your pharmacies from **My pharmacies**. Do not create more than one account for the same person. If you may already have an account, use the recovery option or contact your pharmacy. ### Protect your sign-in Initial MFA verification is required: when prompted by CliniqueRx, enter the single-use code sent to your confirmed email address. Never share this code with anyone. After verification, you may choose to remember your browser for up to 90 days on a device you control. Another browser or loss of this proof may require a new code; a security change or revocation can also end the remembered verification. Remembering the browser does not keep your session open for 90 days. A session lasts at most 24 hours and may end earlier. Use **Sign out** when finished, especially on a shared device. Sharing an IP address does not share your verification with other users. ## 4. Link your account to a pharmacy Your account must be linked to a participating pharmacy before you can access its services. The pharmacy has its own code or invitation process. 1. In **Patient data > My pharmacies**, enter the **Pharmacy discovery code** and select **Request relationship**. This general page is separate from Reflex, Travel and Continuum. 2. Confirm that the pharmacy name is correct. The code creates only a request and does not share clinical information. 3. The pharmacy then verifies your identity and consent. In person, it can approve the relationship directly. Remotely, it uses a channel already known to the pharmacy and then issues a patient-specific one-time invitation. 4. When you receive that invitation, open it while signed in and accept the relationship. 5. Once the relationship is **Approved**, the page shows that pharmacy’s available modules. Select a module to open it directly; Reflex and Travel retain the pharmacy you chose. The menu also provides access to authorized services. The code establishes a relationship with one pharmacy. Do not publish it or use another pharmacy’s code without authorization. ## 5. Sign in safely - Use your own account. - Do not share your password or an invitation link. - Check the site address before entering information. - Avoid public computers or untrusted networks. - Sign out when finished. - If you receive an unexpected request for a password or information, stop and contact your pharmacy through a known method. ### Your home After sign-in, **Home** shows your next steps: forms to finish, a response to read among your recent requests, and your next appointment. Choose **Open my requests**, **Open my agenda**, **Start a consultation**, or **Write a message** as needed. If your basic information is incomplete, a prompt links to your profile for review. **My pharmacies** also lets you establish your first relationship. If a preview cannot be loaded, its unavailability is shown; this does not mean there are no requests or appointments. Open the corresponding section to try again. ## 6. Keep your profile current In **Patient profile**, review information that may help the pharmacist, such as: - date of birth or age; - weight when requested; - pregnancy or breastfeeding, if applicable; - allergies and intolerances; - relevant medicines and health conditions; - contact details used to reach you. Describe what happened during an allergy or intolerance when the form allows it. Do not remove information only because it seems unrelated to your current request. Your profile may fill some answers automatically, but the pharmacist will ask you to confirm that they are still accurate. Update it after an important change. When phone verification is available, you may confirm that you control your number with a one-time code. Verification does not enable SMS by itself. In **Patient profile**, you separately choose, for each approved pharmacy, whether you consent to email reminders, SMS reminders, and follow-up questionnaires. A channel that has not been verified or activated by the platform remains unavailable. ## 7. Start a form You can open a form from **Start consultation** or from a link sent by the pharmacy. ### When you start the request yourself Select the correct pharmacy, describe the concern in your own words, select **Find the minor-complaint assessment**, review the possible assessments, then choose **Continue with my selection**. The portal opens the form directly; no email or SMS is sent for this step. ### When no assessment matches You can choose **Write a message** from **Home**, or open **Write a message to my pharmacy** in the portal, without searching for an assessment. Choose an approved pharmacy, enter your message, then select **Continue to review and send**. Review the message and confirm sending on the next screen. After describing a concern in the search, you may also select **Send a general message to my pharmacy** if none of the suggested forms fits. You may add photos or a voice message when those options are available. This secure message is not a coded clinical assessment, provides no diagnosis, and is not monitored for emergencies. The team reviews it in the Inbox and may contact you to clarify the situation or start the appropriate clinical workflow. ### Resume an interrupted form In **My requests > To finish**, select **Resume** on the clinical form you want. Previously saved answers are restored. Review them and your attachments before confirming submission. The expiry is displayed: resuming does not restart the original 48-hour validity. If the form has expired or access has changed, contact your pharmacy. This feature covers clinical forms linked to your account; unsent general messages are not listed. Finish and send your message before leaving its screen. Forms without an account remain accessible only through the invitation you received. If a form displays **Draft not saved**, select **Retry saving** and wait for confirmation before leaving. You do not need to change a correct answer to retry. ### When the pharmacy sends a link Verify the message and pharmacy before opening the link. The current link expires after 48 hours, is intended for one submission, and must not be forwarded. An invitation **without an account** opens only that form and does not create a patient portal. 1. Check the pharmacy name and service name. 2. Confirm that the form is about the correct person. 3. Read the notice and instructions before starting. 4. Describe the concern in your own words when that field is available. 5. Review the suggested complaints and choose the one that best matches your main concern. 6. Answer based on what you observe now unless the question asks about another time period. Search may display several visually separated complaints when your description could match more than one pathway. It does not make a diagnosis. The list also depends on your pharmacy. If the correct reason is unavailable, contact the pharmacy; do not select a different complaint only to send a form. The illustrated French sheets **Patient-initiated request** and **Form sent by the pharmacy** show the two complete sequences and what happens after submission. ## 8. Answer the questions Questions are presented in short, successive categories. They first check for signs that may require prompt care, then clarify your situation, without telling you which answer represents an emergency, referral, or clinical impression. - Read the whole question and all choices. - Select every requested answer when more than one is allowed. - Use **I don’t know** or **I’m not sure** when true. Do not guess. - At the end of each subsection, select either the findings that are present, the uncertainty option, or **No, none of these signs**; do not simply skip the category. - Add a comment only when it helps explain your answer. - Use **Previous**, **Back**, or the step bar to review a completed section. - After a correction, reread later questions because they may change. An uncertain answer does not automatically block submission. It is clearly shown to the pharmacist, who must clarify it with you before deciding. Some cards include **What to look for** and an illustration. Open only the details that help you. Wording remains plain even though the pharmacist later receives the corresponding clinical finding. ## 9. Add a photo, text, or voice message Some forms allow an attachment or supplementary message. ### Photo The burn and eyelid-problem forms may offer an optional photo. - Take the photo in good light. - Show only the useful area. - When an educational image in the form is clickable, click it to enlarge it before comparing. - Avoid faces, documents, labels, and other unnecessary information. - Never add an intimate photo unless the form clearly requests it and the pharmacy has confirmed the channel. - A photo may help but cannot always show how serious a condition is. ### Text or voice message Briefly explain what started, what changed, and what concerns you. Do not send a password, health card number, or unnecessary information. Check the content before sending; a voice message may be heard by the pharmacist managing the case. ## 10. Burn form The burn form may guide you through several steps: 1. what caused the burn; 2. the person’s age; 3. how it looks, using illustrated examples; 4. where it is on the body; 5. its approximate size. For a small area, you can estimate size using the burned person’s palm. For a large area, the form may show a body map that you can click. Select a region only when most or all of it is burned; for a small part of an arm or leg, use the palm method instead. Images are examples and cannot confirm depth. A burn can change over the following hours or days. If unsure, choose the uncertainty option. After the structured information, the form groups the remaining questions that the diagram cannot infer, followed by a review of your answers. You may attach an optional burn photo when a secure upload area is offered. The pharmacist checks the other important signs and does not decide from the photo alone. ## 11. Review and submit Before submitting: - open the review section; - check every answer and correct errors; - make sure your contact information is accurate; - confirm that attachments are necessary and intended for the correct pharmacy; - read the displayed instructions. After submission, the screen confirms receipt or tells you what to do. Do not submit the same form repeatedly unless the pharmacy asks you to. If your condition changes or worsens, follow safety instructions and notify the pharmacy; do not assume that the old form still describes the situation. ## 12. What the pharmacist does The pharmacist: - reads all answers and attachments; - confirms your identity and profile information; - asks you to clarify uncertain responses; - checks medicines, allergies, and other important factors; - decides whether urgent care, another consultation, or treatment is appropriate; - prepares counselling and follow-up; - records the decision in the applicable record. The outcome may therefore differ from what you expected while completing the form. ## 13. Receive the plan and documents Responses published by your pharmacy in CliniqueRx are available in **My requests** through **Read response**. Home highlights an unread response among your recent requests; open the history for older requests. Depending on the decision, you may receive a printed summary or a document through an approved external channel. Secure in-app email and SMS delivery of the clinical summary is not currently available; confirm with the pharmacy how it will actually be provided. Read: - what was decided; - how to use a product or medicine, if any; - what to watch for; - when follow-up is needed; - when to seek care sooner. If the document has the wrong name, wrong language, an unclear sentence, or an instruction that differs from what the pharmacist explained, do not guess. Contact the pharmacy. ## 14. Agenda, appointments, and follow-ups In **Agenda**, you can view confirmed appointments, follow-ups, and pending change requests. Confirmed appointments shown in your agenda match those in the assigned pharmacy team’s agenda. ### Physical-examination appointments A physical-examination appointment depends on the pharmacy’s configuration: available slots, duration, minimum notice, and any fee. Before treatment begins, you can directly reschedule the appointment when the notice period is still met and another valid slot is available. The screen displays the current fee; if the pharmacy changed it after the original booking, review the new fee before confirming. The new date then replaces the previous date in both agendas. Rescheduling is refused after treatment has started, when minimum notice is no longer met, or when the selected slot is unavailable. ### Follow-up appointments To reschedule or cancel an important post-treatment follow-up: 1. choose the action in **Agenda**; 2. propose the new date and time when rescheduling; 3. submit the request to the pharmacy; 4. wait for the pharmacist’s decision. Your existing appointment remains confirmed and unchanged until the pharmacy approves the request. If it refuses, the existing appointment remains in force. If the pharmacy proposes a new follow-up time, it cannot apply it alone. You must give final confirmation in **Agenda**. Until then, the existing appointment remains confirmed; if you refuse, it does not change. After approval or confirmation, verify the displayed date and time. If your agenda differs from the information provided by the pharmacy, contact it before the appointment. Cancellation in the application does not replace urgent instructions. For an immediate concern, contact the appropriate service directly. ## 15. Vaccination record In **Vaccination record**, you view doses verified and published by your professional. Entries are grouped by vaccine and shown from newest to oldest. The record is read-only: you do not confirm a dose yourself on this page. To have your paper record documented or request a correction, choose **Request a record review**. You can attach photos of the record to that request. A pharmacist or nurse reviews the documents and confirms the doses before publishing them in your history. OSIP VI updates this shared record; OSIP MC consults the same vaccinations. The review request does not include a prescription. A submitted photo or an assisted reading alone does not constitute a confirmed dose or proof that your vaccination is up to date. Follow your professional’s conclusions. ## 16. Continuum — condition follow-up > Linked clinical references, safety libraries, and medication catalogues in > this section are currently available in French only. **Continuum** brings together your longitudinal follow-up by health condition. The core is designed for multiple conditions; hypertension was historically the first specialized pathway, and other validated pathways are now contextualized by condition. You view the conditions and medicines published by your professional, then explicitly select the pharmacy responsible for follow-up when that pharmacy offers you the Continuum module. A Continuum conversation remains linked to a single health condition. Depending on the capabilities specific to the pathway, you and the pharmacist can exchange messages, measurements, targets, forms, proposals, and documents. Specialized blood-pressure functions are not presented as applicable to future pathways without their own validation. You can start and complete any form, questionnaire, score, or clinical value offered in **My clinical values**, even without a request from the pharmacy. Your draft and personal history remain private. You then choose the conversation in which to share a completed result. Your pharmacist can also request a specific instrument; the request link opens the same entry directly but does not allow the pharmacist to see your draft before you explicitly share it. In the hypertension pathway, you can therefore start a private log of 28 blood pressure readings over seven days. Once it is complete, you can copy an immutable snapshot into the hypertension conversation. In the diabetes pathways, you can likewise share the structured AC/PC log covering seven calendar dates or complete it in response to a pharmacist’s request. Your list of medicines and health conditions is read-only in the patient profile. If information is missing or needs correction, request a review from your pharmacy. Direct entry and assisted reading of medicine photos are not offered in this profile. The professional verifies the information before publishing an update. For every condition recognized by Continuum, the pharmacist can propose laboratory follow-up through the same universal form. An accepted proposal remains a clearly marked **non-clinical draft**. It is not a prescription, is neither signed nor transmitted, and does not confirm that a specimen collection or result exists. Always follow your pharmacist’s or laboratory’s explicit instructions. For a medication level, follow the collection time printed on the requisition exactly and do not omit a dose unless specifically instructed. The date and time of the last dose and collection must be recorded. In the adult primary hypothyroidism pathway, the pharmacist can propose the configured TSH target of `0.5 to 5.0 mIU/L`; you can accept it, request further discussion, or refuse it. TSH is a laboratory result: you do not enter it as a patient measurement in Continuum. The pathway’s educational sheet describes possible symptoms to watch for without turning them into a diagnosis or an instruction to adjust a medicine yourself. Before sending you this target, the pharmacist must attest that the adult primary hypothyroidism pathway and its exclusions have been reviewed. In the adult hyperthyroidism pathway, Continuum displays the reference biochemical target: free T4 within the laboratory range, followed by TSH within that range after its lag period. You do not enter free T4, TSH, or a symptom score as a patient measurement. The educational sheet describes possible signs of hyperthyroidism that is still active, alerts specific to methimazole or propylthiouracil, and situations in which you must not wait for a response in Continuum; it never determines whether the target has been reached. In the adult male hypogonadism pathway, testosterone replacement requires compatible symptoms, at least two low morning testosterone blood test results, and an evaluation of the cause. The pharmacist can propose a dual target: improvement in the symptoms documented at baseline and a testosterone level during replacement of approximately `14–17 nmol/L`, adjusted for the product and the timing of the blood draw. You can accept, request further discussion, or refuse this target. Testosterone remains a laboratory result: you do not enter a blood testosterone level, clinical measurement, questionnaire, or symptom score in Continuum. The [educational sheet on signs and symptoms](../../product/continuum-bibliotheque-patient-hypogonadisme-masculin-fr.md) helps you describe what has changed without making a diagnosis. The pathway’s active Canadian choices distinguish injectable cypionate and enanthate, oral undecanoate, transdermal gel, and the intranasal formulation. Long-acting injectable undecanoate, the transdermal solution, and the patch remain inactive until their current Canadian availability is confirmed; they are therefore not offered as active choices. Never change the product, dose, or schedule yourself, and discuss any fertility plans before starting replacement. Details and limitations are recorded in the [pathway’s clinical reference](../../product/continuum-hypogonadisme-masculin-clinical-reference-fr.md) and its [medicine catalogue](../../product/continuum-catalogue-medicaments-hypogonadisme-masculin-fr.md). In the menopausal vasomotor symptoms pathway, the pharmacist can propose a target of a clinically meaningful reduction in the frequency and severity of hot flashes and night sweats, with improved sleep, function, and quality of life. You can accept this goal, request further discussion, or refuse it. Acceptance confirms the agreed target; it does not mean that the improvement has already been achieved. You do not complete a hot-flash diary, score, questionnaire, hormone level, or other clinical measurement for this target in Continuum. You can describe the change in your own words in the conversation without it being converted into a measurement or automatically prompting a treatment change. The choice of treatment depends in particular on the presence of a uterus, bleeding, a history of thrombosis or hormone-sensitive cancer, the liver, migraine, and interactions. With a uterus, systemic estrogen usually requires endometrial protection; a levonorgestrel-releasing intrauterine system used for this purpose is an off-label use that must be confirmed for the specific device. VEOZAH and LYNKUET are two separately marketed neurokinin antagonists; their monitoring is not interchangeable. Never start, stop, or change a product, dose, or route yourself. The pathway’s [safety library](../../product/continuum-bibliotheque-patient-symptomes-vasomoteurs-menopause-fr.md) distinguishes a possible thrombosis in one leg, which requires urgent same-day assessment, from possible signs of pulmonary embolism—sudden shortness of breath, chest pain, coughing up blood, or loss of consciousness—which require calling **911** without waiting for Continuum. It also describes the planned liver tests and the symptoms that require immediate assessment while taking fezolinetant/VEOZAH. See the [pathway’s clinical reference](../../product/continuum-symptomes-vasomoteurs-menopause-clinical-reference-fr.md) and its [medicine catalogue](../../product/continuum-catalogue-medicaments-symptomes-vasomoteurs-menopause-fr.md). In the genitourinary syndrome of menopause pathway, the pharmacist can propose as a target an improvement in whichever of these symptoms bother you: dryness, burning, irritation, pain during intercourse, and urinary symptoms. The target can also include sexual function and quality of life if they are part of your goal. You can accept this goal, request further discussion, or refuse it. Acceptance confirms the agreed target; it does not mean that the improvement has already been achieved. You do not enter any biological or instrumental value, clinical measurement, or symptom score for this target. Its progress is discussed with your team. The published Canadian medicine choices distinguish vaginal estradiol as a tablet, insert, or ring, conjugated estrogen vaginal cream, vaginal prasterone, and oral ospemifene; no systemic formulation is substituted automatically. Postmenopausal bleeding or a concerning symptom requires a separate assessment. See the [pathway’s clinical reference](../../product/continuum-sgum-clinical-reference-fr.md) and its [medicine catalogue](../../product/continuum-catalogue-medicaments-sgum-fr.md). The [GSM patient library](../../product/continuum-bibliotheque-patient-sgum-fr.md) also provides three printable instruction sheets: the disposable preloaded Vagifem 10 applicator, the reusable graduated Premarin vaginal cream applicator, and the Intrarosa applicator, which must be rinsed and then replaced after one week. Each step has an original product-specific CliniqueRx visual; the text and official package insert take precedence if the appearance differs. Always check the exact product name: Imvexxy and Estring are inserted manually, without these applicators. In the essential tremor pathway, implemented on August 30, 2026, the pharmacist can propose as a target a subjective improvement in your tremors and in your ability to carry out the activities that you prioritized together. You can accept this goal, request further discussion, or refuse it. Acceptance confirms the agreed target; it does not mean that the improvement has already been achieved. You describe the change in your own words in the conversation. For this target, you do not complete any structured clinical measurement, score or threshold, questionnaire, or diary. Tremor assessment tools exist in clinical practice, but they are not enabled in this pathway. The candidate medicines are propranolol and primidone as first-line options; topiramate, gabapentin and, in selected cases, atenolol, nadolol, or sotalol as alternatives; and alprazolam or clonazepam on a limited basis. OnabotulinumtoxinA is a specialist-managed option for refractory focal tremor; its benefit for activities can be inconsistent, weakness can occur, and this use is off-label in Canada. A medicine’s presence in the catalogue is not a recommendation and never automatically changes your treatment. See the [pathway’s clinical reference](../../product/continuum-tremblement-essentiel-clinical-reference-fr.md) and its [medicine catalogue](../../product/continuum-catalogue-medicaments-tremblement-essentiel-fr.md). In the fibromyalgia pathway, implemented on August 30, 2026, you can record four separate whole-number ratings from `0` to `10`: functional limitation, sleep disruption, fatigue, and pain. For each domain, `0` means no burden or impact and `10` means the greatest burden or impact imaginable. The four ratings form a single dated observation, but they are never added together or averaged. This is not a validated questionnaire, an official score, or a composite result. For each domain, Continuum displays the change in points since your first active complete observation. A one-point improvement on the scale represents 10 percentage points of its fixed range; this does not mean “10% improvement” and is not a validated clinical response threshold. A negative value indicates worsening and is not reset to zero. For pain only, the follow-up target is a relative reduction of at least **30%** from your first active pain rating that predates the current one and is strictly positive. If there is not yet an earlier positive rating, or if the only reference is `0`, this calculation remains indeterminate. It draws no conclusion about function, sleep, or fatigue and never prompts a medicine change. The overall target remains an individualized improvement across all four domains, without requiring the pain to disappear. You can start this entry yourself or respond to a pharmacist’s request. Your observations remain private until you explicitly choose which one to share in the fibromyalgia conversation. The pharmacist then receives a snapshot of the four ratings, not your drafts. The pathway’s candidate medicines are duloxetine, pregabalin, amitriptyline, gabapentin, cyclobenzaprine, venlafaxine, fluoxetine, and short-term tramadol. Cannabinoids require identification of a specific product, and low-dose naltrexone remains off-label; these two limited-evidence references are not active suggestions. Never start, stop, or combine a treatment yourself based on a rating or displayed result. The [resource sheet for living with chronic pain](../../product/continuum-bibliotheque-patient-fibromyalgie-fr.md) points in particular to the CHUM document **Vivre avec une douleur chronique**. Also see the [pathway’s clinical reference](../../product/continuum-fibromyalgie-clinical-reference-fr.md) and its [medicine catalogue](../../product/continuum-catalogue-medicaments-fibromyalgie-fr.md) for the complete limitations. In a documented gout pathway, your pharmacist can propose a serum urate target of `< 360 µmol/L` during urate-lowering treatment. A lower target of `< 300 µmol/L` can be proposed when tophi, chronic gouty arthropathy, or frequent flares are documented. You can accept the proposal, request further discussion, or refuse it. Only your acceptance creates an agreed, versioned target. Serum urate is a laboratory result: you do not enter an urate value as a clinical measurement in Continuum. The application does not decide whether the target has been reached and never changes your treatment based on a result. Do not start, stop, or change any medicine without your health care professional’s instructions. The [“Gout: diet and lifestyle” sheet](../../product/continuum-bibliotheque-patient-goutte-fr.md) summarizes realistic changes concerning alcohol, sugary drinks, animal purines, and gradual weight loss when it is right for you. It also explains why plant proteins do not need to be banned and why no food or supplement replaces treatment. See the [clinical reference](../../product/continuum-goutte-clinical-reference-fr.md) and the [medicine catalogue](../../product/continuum-catalogue-medicaments-goutte-fr.md) for the complete limitations. In the fragility-fracture prevention pathway, you work with your team to prepare a **shared decision**, not a value to reach. Baseline risk, FRAX, bone mineral density, and the T-score can inform the discussion, but you do not enter them as clinical measurements in Continuum. CliniqueRx neither calculates nor imports FRAX, does not diagnose osteoporosis, and does not automatically choose a medicine. The [“Preventing a fracture: decide based on your risk” sheet](../../product/continuum-bibliotheque-patient-prevention-fractures-fr.md) opens the external Canadian tool in your language. It helps you compare, among 100 people, the risk without medicine and the possible absolute benefit of preventive pharmacotherapy, then discuss adverse effects, burden, uncertainty, and your preferences. Bisphosphonates are the main option presented; the tool does not directly compare medicines with one another. It is intended for a specific screening population and notably excludes people already considered at high risk or already receiving treatment; your team must confirm whether it applies to your situation. Options the team can discuss include alendronate, risedronate, and zoledronic acid as first-line options; denosumab or raloxifene in selected situations; and teriparatide or romosozumab with specialist input. Etidronate is only a disabled historical reference. Calcium-rich foods, vitamin D based on age and context, physical activity, balance, strengthening, and fall prevention are also part of the plan. Never start, delay, stop, or change a treatment yourself. See the [clinical reference](../../product/continuum-prevention-fractures-clinical-reference-fr.md) and the [medicine catalogue](../../product/continuum-catalogue-medicaments-prevention-fractures-fr.md) for the complete limitations. In the “Primary cardiovascular risk / dyslipidemia” pathway, you also prepare a **shared decision**, rather than a cholesterol number to reach in Continuum. The goal is to prevent a first major cardiovascular event over the long term, particularly a heart attack or stroke. The Framingham score, lipid panel, and other risk factors can inform the discussion, but you do not enter them as clinical measurements. CliniqueRx neither calculates nor imports the score and does not automatically choose a treatment. The [“Preventing a cardiovascular event: decide based on your risk” sheet](../../product/continuum-bibliotheque-patient-prevention-cardiovasculaire-primaire-fr.md) opens the external PEER tool. It helps you compare absolute risk, possible benefit, adverse effects, and what matters to you. It also presents a Mediterranean-style diet, physical activity suited to you, smoking cessation, and other modifiable factors. The external site has its own privacy practices; CliniqueRx does not send it any data and does not receive its result. Statins are the first-line class when your risk, context, and preferences support pharmacotherapy. Non-statins, fibrates, prescribed omega-3s, and icosapent ethyl have more selected roles and are not interchangeable. Never start, stop, or combine a treatment yourself based on the score or this sheet. See the [clinical reference](../../product/continuum-prevention-cardiovasculaire-primaire-clinical-reference-fr.md) and the [medicine catalogue](../../product/continuum-catalogue-medicaments-prevention-cardiovasculaire-primaire-fr.md) for the complete limitations. In the chronic kidney disease pathway, you also prepare a **shared decision**, with no number to reach in Continuum. The goal is to slow disease progression and reduce or delay the risk of kidney failure treated with dialysis or transplantation. eGFR, the urine albumin-to-creatinine ratio, and their changes inform follow-up, but you do not enter them as clinical measurements in this pathway. The [“Protecting the kidneys: understand risk and decide together” sheet](../../product/continuum-bibliotheque-patient-maladie-renale-chronique-fr.md) opens the external Kidney Failure Risk Equation. In an adult with G3 to G5 CKD, this tool estimates risk at 2 and 5 years based on age, sex, eGFR, and the urine albumin-to-creatinine ratio. The site has its own privacy practices; CliniqueRx does not send it any data, does not calculate or import the result, and does not use any threshold to choose a treatment, a referral, or the start of dialysis. The KFRE estimates your baseline risk, not the individual benefit of a medicine. The sheet therefore separately compares the possible benefits, adverse effects, monitoring, and burden of medicines that slow progression and those that manage fluid overload, acidosis, hyperkalemia, anemia, or mineral and bone disorder. These complications have distinct treatments and tests. Never start, stop, or change a treatment yourself based on the KFRE or this sheet. Advice on sodium, fluids, potassium, phosphorus, and protein is individualized based on your stage, results, dialysis, other health conditions, and risk of malnutrition; there is no universal list of prohibited foods. A dietitian specializing in nephrology can adapt the plan. See the [clinical reference](../../product/continuum-maladie-renale-chronique-clinical-reference-fr.md) and the [medicine catalogue](../../product/continuum-catalogue-medicaments-maladie-renale-chronique-fr.md) for the complete limitations. In case of severe shortness of breath, chest pain, loss of consciousness, new confusion, seizures, profound weakness, a new marked decrease in urine compared with your usual level, or rapidly worsening swelling, obtain urgent help without waiting for Continuum; call `9-1-1` if the symptoms are severe. The Continuum pathway for documented chronic GERD is distinct from **Acute Reflex**. The pharmacist can propose the target “resolution or acceptable control of heartburn and regurgitation, with restored sleep and quality of life; endoscopic healing if erosive esophagitis is documented.” You can accept it, request further discussion, or refuse it; only your acceptance creates the agreed target. No clinical measurement is collected. The [sheet on lifestyle habits and `H. pylori`](../../product/continuum-bibliotheque-patient-reflux-gastro-oesophagien-fr.md) also explains when to discuss testing with your team. ## 17. Travel health In **Travel health**, enter each actual destination or itinerary stop with dates. Include transit points, visited regions, activities, and requested details. A country alone is not always enough because recommendations can differ by region and altitude. The tool uses the INSPQ Travel Health Guide throughout Canada. It can help the pharmacist consult recommendations and prepare a schedule. The pharmacist must verify everything against current recommendations. Do not change vaccines or medicines based only on a displayed result before that review. ## 18. Use a link without an account The pharmacy may send you a temporary link by email or SMS. It provides access to the specific form, not a complete patient portal. - Confirm that the message truly came from your pharmacy. - Do not forward the link. - Complete it before it expires; the current link is valid for 48 hours and one submission. - If it no longer works, ask the pharmacy for a new one. - The submitted case remains managed by the pharmacy that invited you. ## 19. Privacy and your choices Provide only information needed for your request. Use a private setting and a device you trust. You can ask the pharmacy how your information is used, corrected, retained, or transferred to the official record. If you believe you sent information to the wrong pharmacy, shared the wrong file, or lost control of your account, contact the pharmacy immediately using a known method. Do not place health information in an unprotected general support message. ## 20. Technical problem If a page does not open or a button does not respond: 1. note the step and displayed message; 2. avoid submitting the form repeatedly; 3. do not take a screenshot containing personal information unless the pharmacy provides secure instructions; 4. contact the pharmacy; 5. in an emergency or if the condition worsens, obtain necessary care without waiting for the site to recover. ## 21. Unavailable functions and current status - CliniqueRx makes no final decision without pharmacist review. - This edition describes Global production workflows. Enter real information only through an authorized pharmacy workspace; use fictional data for demonstrations, screenshots, and training. For a personal-information request or privacy complaint, contact the CliniqueRx Privacy Officer at `jean-philippe.caron@clinique-rx.com`. Do not include health information in ordinary email. For clinical or operational support, contact your pharmacy using a known method.